Noxopharm raises $1.05 million to advance lupus drug trial
What's the deal? Australian clinical-stage biotech NoxopharmDealroom has a profile for this one. Try Dealroom → has secured commitments for US$970.6K (roughly $1.05 million) through a share placement to professional and sophisticated investors. The shares were priced at US$0.03 each — a 19.2% discount to the last traded price on October 26 — issuing about 35.7 million new shares.
Who's backing it? Chairman Fred Bart subscribed for US$242.6K, subject to shareholder approval at a general meeting expected in mid-December 2026. The placement sits alongside an early conversion of US$2.45M in shareholder convertible notes and a planned share purchase plan targeting up to US$647.1K more.
What's the endgame? Proceeds will fund an extension study of lead program SOF-SKN in patients with cutaneous lupus erythematosus, starting in the first quarter of 2027. The money also supports regulatory-enabling work for a planned Phase 2 trial and preclinical development of other programs on Noxopharm's Sofra platform.
Why now? The raise follows a Phase I trial in healthy volunteers that reported a favourable safety profile. "With our lead program (SOF-SKN) approaching its next stage of clinical evaluation, the Equity Raising and early Note conversion comes at an important time," said chief executive officer Olivier Laczka.
What could go wrong? The placement is modest against the company's needs. Its June 2026 quarterly report flagged that more funding would be required and disclosed a US$129.4K short-term loan from an entity linked to its chairman, plus a US$3.24M at-the-market facility.
The signal: For a clinical-stage biotech, this is near-term runway rather than a cushion. It buys Noxopharm enough to chase early efficacy signals in cutaneous lupus — but the costlier, riskier work of advancing through later trials still lies ahead.
Read more: listcorp.com
Image credit: Generated with Gemini
